Research
Hormonal
Randomized trials with liraglutide and semaglutide have shown reductions in major adverse cardiovascular events.
These medications may be beneficial for patients at high risk of cardiovascular events.
StrongSupportsmedium confidence
In high-risk populations, randomized trials with liraglutide and semaglutide have also shown reductions in major adverse cardiovascular events.
Why this rating
Based on randomized trials mentioned in the abstract.
Source
Cardiovascular effects of anti-obesity medications: the perils and promise
Haoyi Zheng · Cardiology Plus · 2025
DOI 10.1097/cp9.0000000000000114
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →